With significant clinical and regulatory precedents already established, Ocuphire Pharma is advancing quickly and preparing for upcoming milestones
It’s practically inevitable: as we age, our eyes don’t function like they used to. We could just say that it’s part of life – or we can work aggressively to address these limiting conditions, and that’s precisely what Ocuphire Pharma (OCUP) is doing.
You might have guessed it from the name of the company: Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders.
The company’s highly focused pipeline currently includes two small-molecule product candidates targeting eye conditions for both the front and the back of the eye – thereby helping more patients and serving a wider market.
Best of all, Ocuphire’s two product candidates are relatively non-invasive and the clinical trials are progressing quickly with an encouraging success rate – and recently released positive top-line results prove the point.
A Closer Look at OCUP Stock
Buy low, sell higher – that’s the credo of successful investors, and it’s a strategy that can produce astounding returns if you can identify high-conviction stock set-ups.
OCUP stock presents a textbook example of a buy-low opportunity as the stock is sitting right at a proven support level. Back in November of last year, the stock came down to the $4 area – and what happened next was a powerful moment for well-timed investors.
In a stunning reversal, OCUP rocketed higher – but calm-minded professionals knew that “selling higher” means letting your winners run. And they were 100% right as OCUP kept on going until it reached an amazing short-term high of $13.31 in early February.
Now, the smart money has a second chance to accumulate shares of OCUP stock near that same $4 support level. You can thank me later if the stock rockets to $13 again – and if the momentum is there, then you can hold your shares for even greater gains.
Two Products for Both Sides of the Eye
In pursuit of a vast and largely under-addressed market, Ocuphire Pharma is advancing two exciting products which, for selected indications, are already far along the clinical and regulatory path towards commercialization.
That’s why Ocuphire can be characterized as a “late-stage” clinical drug maker – it’s a huge advantage as the company’s working on eye disease treatments that already have track records.
Ocuphire two flagship products in development are:
- Nyxol eye drops, which target multiple chronic and acute front-of-the-eye indications addressing large markets: dim light/night vision disturbances (U.S. prevalence: ~16 million adults), reversal of mydriasis (~100 million pupil dilations per year in the U.S), and presbyopia (U.S. prevalence: ~120 million adults)
- APX3330 tablets, which target chronic back-of-the-eye indications: diabetic retinopathy (U.S. prevalence: ~7 million adults) and diabetic macular edema (U.S. prevalence: ~750,000 adults), a leading cause of blindness in diabetic patients
Thus, Ocuphire’s products address a range of conditions on both sides of the eye – and hundreds of millions of patients, representing addressable markets valued at hundreds of billions of dollars.
In fact, the markets for Nyxol and APX330 each cover between $4 billion and $10 billion. We can anticipate that patient compliance won’t be a major issue as the delivery methods – single-use, preservative-free eye drops and a pill – are quite non-invasive compared to some other severe eye-disease treatment methods.
Promising Clinical Data
Since Ocuphire is advancing products that already have a successful clinical track record, this can make it quicker and easier to achieve new breakthrough moments for these drug candidates.
And indeed, Nyxol and APX3330 have already achieved promising clinical data over multiple Phase 1, 2, and 3 trials. Specifically, more than 250 patients have been treated across 8 clinical trials with Nyxol, while over 340 patients have been treated across 11 trials with APX3330.
Moreover, these two products should provide enduring revenue sources as Ocuphire has obtained U.S. and globally issued patents through 2034 for both assets.
Furthermore, in a fresh press release, Ocuphire revealed positive MIRA-2 Phase 3 results for Nyxol eye drops, which indicate sustained efficacy with a favorable safety profile in reversing mydriasis.
The findings were extremely encouraging:
- The trial met its primary clinical endpoint at 90 minutes with high statistical significance with 2 drops of Nyxol
- Met all key secondary endpoints with high statistical significance:
1. Efficacy for all 3 mydriatic agents – phenylephrine, tropicamide, and Paremyd
2. Efficacy in both light and dark iris colors
3. Efficacy with only one Nyxol drop in non-study eye
- A favorable safety profile was established, with no serious adverse events
The Bottom Line
If you’re ready to take a long position in OCUP stock, then it’s trading exactly where it ought to be: in the “buy low” zone, though it might not stay there for much longer.
Meanwhile, Ocuphire Pharma is poised to disrupt the eye-care market – and provide groundbreaking solutions to address both sides of the eye for millions of patients – with a laser-focused product pipeline that’s already got plenty of positive clinical data on the books.
